has function has role immunizes against disease immunizes recipient test in lab animal model brain cancer multiple myeloma Mus musculus Homo sapiens therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role brain cancer vaccine myeloma cancer vaccine SVN53-67/M57-KLH peptide vaccine Jimmy Guo A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response. 5008 Gene name: Survivin PMID:27576783 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5008 cancer vaccine Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95705 NCT: https://clinicaltrials.gov/ct2/show/NCT02334865 373110 https://github.com/vaccineontology/VO/issues/405 Oliver He Jie Zheng therapeutic cancer vaccine